E3311 is a phase II randomized study that showed that low-dose radiation at 50 Gy without chemotherapy following transoral surgery (TOS) led to very high survival and outstanding quality of life in patients with human papillomavirus-positive (HPV+) throat cancer and at medium risk for recurrence. A planned analysis of patient outcomes by tobacco history found no differences in progression-free survival (PFS) or overall survival (OS) outcomes at three years between patients with less than or greater than ten pack-year smoking history as well as current versus former smokers. Ranee Mehra, MD, (University of Maryland Marlene & Stewart Greenebaum Cancer Center) presented the data at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.
E3311study chair Barbara Burtness, MD (Yale Cancer Center), highlighted the trial in a May 2020 interview with VJ Oncology.
Ari Rosenberg, MD (University of Chicago), discussed the rationale behind the E3311 trial in this June 2022 interview.